Gilead Sciences: Harvoni “Off to the Races”
October 24, 2014 at 09:32 AM EDT
Gilead Sciences’ (GILD) new Hepatitis-C treatment Harvoni just hit the market–and it’s “off to the races,” says UBS analyst Matthew Roden and team. They explain: Scripts for Gilead’s Harvoni during the week ending October 17 were released today with total scripts of 445 for the first five days on the market. This implies a total [...]
